A Clinical Trial of the Accuracy and Treatment Experience of the Dexcom G4 Sensor (Dexcom G4 System) and Enlite Sensor (Guardian REAL-Time System) Tested Simultaneously in Ambulatory Patients with Type 1 Diabetes
- 1 November 2014
- journal article
- research article
- Published by Mary Ann Liebert Inc in Diabetes Technology & Therapeutics
- Vol. 16 (11), 759-767
- https://doi.org/10.1089/dia.2014.0238
Abstract
Background: Continuous glucose monitoring (CGM) is a tool widely used in the treatment of patients with type 1 diabetes. The purpose of the current study was to evaluate whether accuracy and patient treatment satisfaction differ between the Enlite™ (Medtronic MiniMed, Inc., Northridge, CA) and Dexcom® (San Diego, CA) G4 PLATINUM CGM sensors. Subjects and Methods: Thirty-eight ambulatory patients with type 1 diabetes used the Dexcom G4 and Enlite sensors simultaneously for a minimum of 4 and maximum of 6 days. Patients measured capillary glucose levels with a HemoCue® (Ängelholm, Sweden) system six to 10 times a day. In addition, two inpatient studies were performed between Days 1–3 and 4–6. Results: The mean absolute relative difference (MARD) in blood glucose for the Dexcom G4 was significantly lower (13.9%) than for the Enlite sensor (17.8%) (PP=0.0027) and 13.6% versus 15.9% (P=0.026) for Days 4–6. For glucose levels in the hypoglycemic range (P=0.0041). On a visual analog scale (VAS) (0–100), patients rated the Dexcom G4 more favorably than the Enlite in 12 out of the 13 user experience questions. For example, more patients rated their experience with the Dexcom G4 as positive (VAS, 79.7 vs. 46.6; PPConclusions: The Dexcom G4 sensor was associated with greater overall accuracy than the Enlite sensor during initial (Days 1–3) and later (Days 4–6) use and for glucose levels in the hypoglycemic range. Patients reported a significantly more positive experience using the Dexcom G4 than the Enlite.Keywords
This publication has 20 references indexed in Scilit:
- Performance Comparison of the Medtronic Sof-Sensor and Enlite Glucose Sensors in Inpatient Studies of Individuals with Type 1 DiabetesDiabetes Technology & Therapeutics, 2013
- Risk of Cardiovascular Disease and Total Mortality in Adults with Type 1 Diabetes: Scottish Registry Linkage StudyPLoS Medicine, 2012
- Response to Comment on: Maruthur et al. Does Genetic Ancestry Explain Higher Values of Glycated Hemoglobin in African Americans? Diabetes 2011;60:2434–2438Diabetes, 2011
- Cause-Specific Mortality Trends in a Large Population-Based Cohort With Long-Standing Childhood-Onset Type 1 DiabetesDiabetes, 2010
- Associations Between Features of Glucose Exposure and A1CDiabetes, 2010
- Factors Predictive of Use and of Benefit From Continuous Glucose Monitoring in Type 1 DiabetesDiabetes Care, 2009
- Comparison of the Numerical and Clinical Accuracy of Four Continuous Glucose MonitorsDiabetes Care, 2008
- Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 DiabetesThe New England Journal of Medicine, 2005
- The British Diabetic Association Cohort Study, I: all‐cause mortality in patients with insulin‐treated diabetes mellitusDiabetic Medicine, 1999
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusThe New England Journal of Medicine, 1993